Fluciclatide F-18
Alternative Names: [18F]AH111585; AH111585-18FLatest Information Update: 18 Oct 2018
At a glance
- Originator GE Healthcare
- Developer GE Healthcare; National Cancer Institute (USA)
- Class Imaging agents; Peptides; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 18 Oct 2018 Discontinued - Phase-II for Solid tumours (Diagnosis) in South Korea (IV)
- 18 Oct 2018 Discontinued - Phase-II for Solid tumours (Diagnosis) in USA (IV)
- 27 Feb 2016 Asan Medical Center terminates phase II trial in Solid tumours (Diagnosis) in South Korea (NCT01961583)